Medical cannabis for nerve pain has documented side effects but safety data remains incomplete for most products
While nabiximols is the only cannabis product approved and pharmacovigilance-monitored for neuropathic pain, the wide variety of other cannabis preparations used for pain lack adequate safety data.
Quick Facts
What This Study Found
Only nabiximols (a balanced CBD/THC product) is approved by regulatory authorities for neuropathic pain and included in pharmacovigilance systems. The many other cannabis preparations widely used for chronic nerve pain are unmonitored, creating insufficient knowledge of their safety profiles.
Key Numbers
Nabiximols contains similar percentages of CBD and THC; approved in many European countries and Canada for neuropathic pain and MS-related spasticity
How They Did This
Review of published clinical studies reporting adverse reactions from cannabis use for neuropathic pain relief.
Why This Research Matters
Millions of people use various cannabis preparations for chronic nerve pain, but without systematic safety monitoring, the true risk-benefit profile of most products remains unknown.
The Bigger Picture
The gap between the single approved cannabis pain product and the dozens of unregulated products people actually use highlights a broader regulatory challenge as medical cannabis use expands globally.
What This Study Doesn't Tell Us
Safety data limited to published clinical studies, which may not capture all real-world adverse reactions. Heterogeneous cannabis products make direct comparisons difficult.
Questions This Raises
- ?Should cannabis preparations for pain be subject to the same pharmacovigilance requirements as approved medications?
- ?How do adverse effect profiles differ between various cannabis formulations used for pain?
Trust & Context
- Key Stat:
- Only one cannabis product (nabiximols) is approved and safety-monitored for neuropathic pain
- Evidence Grade:
- Review of clinical study data with focus on adverse reactions from cannabis pain treatments
- Study Age:
- Published in 2021. The landscape of available cannabis products for pain continues to expand.
- Original Title:
- Safety of Medical Cannabis in Neuropathic Chronic Pain Management.
- Published In:
- Molecules (Basel, Switzerland), 26(20) (2021)
- Authors:
- Bennici, Alessandra, Mannucci, Carmen(3), Calapai, Fabrizio(2), Cardia, Luigi, Ammendolia, Ilaria, Gangemi, Sebastiano, Calapai, Gioacchino, Griscti Soler, Daniel
- Database ID:
- RTHC-02997
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Is medical cannabis safe for nerve pain?
The safety profile is well-documented only for nabiximols, the sole approved cannabis product for neuropathic pain. Most other cannabis preparations used for pain lack systematic safety monitoring.
What is nabiximols?
Nabiximols is a cannabis-derived product containing balanced amounts of CBD and THC, approved in many European countries and Canada for neuropathic pain and spasticity related to multiple sclerosis.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-02997APA
Bennici, Alessandra; Mannucci, Carmen; Calapai, Fabrizio; Cardia, Luigi; Ammendolia, Ilaria; Gangemi, Sebastiano; Calapai, Gioacchino; Griscti Soler, Daniel. (2021). Safety of Medical Cannabis in Neuropathic Chronic Pain Management.. Molecules (Basel, Switzerland), 26(20). https://doi.org/10.3390/molecules26206257
MLA
Bennici, Alessandra, et al. "Safety of Medical Cannabis in Neuropathic Chronic Pain Management.." Molecules (Basel, 2021. https://doi.org/10.3390/molecules26206257
RethinkTHC
RethinkTHC Research Database. "Safety of Medical Cannabis in Neuropathic Chronic Pain Manag..." RTHC-02997. Retrieved from https://rethinkthc.com/research/bennici-2021-safety-of-medical-cannabis
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.